Skip to main content

Clinical Trials

Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy

Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials

Jacqueline Saunders, PharmD, BCPS; Sumati Murli, PhD; Michelle A. Rudek, PharmD, PhD; Anand Khandoobhai, PharmD, MS; Anne DeLisa, PharmD, CCRP; Amy Goodrich, RN, MSN, CRNP-AC; Janet Mighty, BS Pharm, MBA

Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice

Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study

Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program

Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study

Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC

Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study

Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study

1
2

Page 1 of 2
Results 1 - 10 of 14